Supernus Pharmaceuticals Inc (SUPN)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	81,666	59,265	26,558	-13,598	-5,269	30,061	20,400	49,333	46,124	17,888	52,015	74,782	86,029	122,929	146,465	157,900	173,698	171,516	155,105	152,155
Revenue (ttm)	US$ in thousands	661,817	654,387	632,578	598,906	607,521	619,414	641,163	674,751	673,056	651,277	618,187	585,808	560,079	545,016	551,524	536,576	506,717	465,383	418,476	402,257
Operating profit margin		12.34%	9.06%	4.20%	-2.27%	-0.87%	4.85%	3.18%	7.31%	6.85%	2.75%	8.41%	12.77%	15.36%	22.56%	26.56%	29.43%	34.28%	36.85%	37.06%	37.83%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $81,666K ÷ $661,817K
= 12.34%

The operating profit margin of Supernus Pharmaceuticals Inc has shown a declining trend over the past few years. Starting at a robust 37.83% in March 31, 2020, the margin gradually decreased to 12.77% in March 31, 2022, indicating a decreasing profitability in generating operating income relative to revenue.

However, after reaching a low point of -2.27% in June 30, 2024, the operating profit margin started to recover, showing positive signs of improvement. By December 31, 2024, the operating profit margin had increased to a healthier 12.34%.

This improvement suggests that Supernus Pharmaceuticals Inc may have implemented strategic measures to enhance its operational efficiency and profitability. Further analysis and monitoring of the company's financial performance will be vital to assess the sustained turnaround in operating profit margin.